固相法合成多肽AN-M的工艺研究

目的:探讨生物活性肽AN-M的固相合成工艺,并为工业化合成目的肽提供理论依据。方法采用固相法,以Fmoc-保护基保护的α-氨基酸和Wang树脂为原料,经1—氧—3—双二甲胺羧基苯骈三氮唑四氟化硼盐(TBTU)、1—羟基苯并三氮唑(HoBt)、二异丙基乙胺(DIEA)缩合,20%哌啶的DMF溶液脱保护,用切割试剂将AN-M粗品从Wang树脂上切割下来。结果经反相高效液相色谱分析纯化,可得目的肽的得率大于67．00%,最终成品的纯度在98．78%以上,经质谱鉴定其分子量与理论值一致。结论该合成方法步骤简便、便于操作、产品得率高,可用于大规模合成目的肽。     

用RT-PCR验证抗-HCV C100和抗-HCV CP检测系统的特异性

本文检测了几种人群中HCV C100抗原的抗体(抗-C100)和HCV核心抗原的抗体(抗-CP)的阳性率。输血后NANB肝炎中抗体阳性率最高(抗-C100:58.7％;抗-CP:71.7％),其次为未知病因NANB肝炎(抗-C100:26.2％,抗-CP:38.5％)和血液病人(抗-C100:15.0％,抗-CP:31.7％);而急性散发性肝炎中的抗体阳性率较低(抗-C100:8.9％,抗-CP:15.5％)。成年人中二种抗体阳性率分别为1.8％和2.8％。在各科人群中抗-CP阳性率明显高于抗-C100,表明抗-CP是检测HCV感染的十分有用的指标。同时本文还用RT-PCR法验证了抗-C100和抗-CP检测系统的特异性,发现抗-CP和HCVRNA有良好的相符性,而抗-C100和HCVRNA的相符性较差,因此推测抗-CP检测系统比抗-C100检测系统有较高的特异性。     

利用大肠杆菌表达系统制备抗VEGF螺旋-环-螺旋多肽及其纯化的研究

VEGF(血管内皮生长因子)是一种诱导肿瘤血管形成的作用最强、特异性最高的血管生长因子.本实验利用抗VVEGF螺旋-环-螺旋多肽的基因M49,通过PCR技术扩增获得目的基因,构建原核表达pET-32a(+),转入大肠杆菌(Escherichia coli)BL21进行表达,并对目的蛋白进行诱导表达及纯化.结果表明PCR...     

人工合成多肽检测抗HIV－1和HIV－2抗体的研究

采用固相法合成ＨＩＶ－１和ＨＩＶ－２两个多肽,建立了用混合多肽为包被抗原检测ＨＩＶ－１和ＨＩＶ－２感染的间接酶联免疫吸附法。检测４６份抗ＨＩＶ－１和ＨＩＶ－２抗体阳性血清标本以及９４份对照血清标本,与ＵＢＩ试剂比较,其阳性符合率为９７．８％,阴性符合率为１００％,总符合率为９９．３％。实验结果表明,此法可用于ＨＩＶ－１和ＨＩＶ－２感染的检测。     

HIV感染的辅助因子—融合素

ＨＩＶ感染的辅助因子——融合素黄仕和秦椿华（卫生部武汉生物制品研究所,武汉４３００６０）（同济医科大学工业毒理研究室,武汉４３００３０）关键词融合素ＨＩＶ感染１９８４年,研究者发现,ＨＩＶ感染细胞是通过细胞表面受体ＣＤ４进行的。二年后又发现,仅有ＣＤ...     

蝎毒多肽Ctry2459抗白色念珠菌机制研究

【目的】探究蝎毒多肽Ctry2459抗白色念珠菌的作用机制。【方法】采用肉汤稀释法并结合平板计数法测定蝎毒多肽Ctry2459对白色念珠菌的最小抑菌浓度和最小杀真菌浓度;通过平板计数法绘制蝎毒多肽Ctry2459对白色念珠菌的时间-杀菌动力学曲线;通过PI吸收实验检测蝎毒多肽Ctry2459对白色念珠菌细胞膜完整性的影响;通过核酸阻滞实验检测蝎毒多肽Ctry2459与核酸间是否具有结合作用;通过流式细胞技术检测蝎毒多肽Ctry2459对白色念珠菌活性氧、线粒体膜电位以及凋亡/坏死的影响。【结果】蝎毒多肽Ctry2459对白色念珠菌的最小抑菌浓度和最小杀真菌浓度分别为25μg/mL和50μg/mL。蝎毒多肽Ctry2459对白色念珠菌的杀菌作用具有时间和浓度依赖性,并可通过直接破坏细胞膜的完整性以及通过ROS介导的线粒体失能导致细胞坏死的方式杀灭白色念珠菌细胞。【结论】蝎毒多肽Ctry2459可以作为抗白色念珠菌药物研发的候选分子或者分子模板。     

整细胞酶促合成抗HIV新药 D-D4FC

D-D4FC(β-D-2′,3′-双脱氢双脱氧-5-氟胞嘧啶核苷)是一种新型抗HIV病毒的核苷类药物,目前正在美国、法国和德国进行Ⅱ期临床。利用乳酸杆菌提取的粗制N-脱氧核糖转移酶实现了由D4T(β-D-2′,3′-双脱氢双脱氧-胸苷,司他夫定)和5-FC(5-氟胞嘧啶)合成D-D4FC,转化率达到25%。现在,发现利用乳酸杆菌整细胞也可实现此反应,其转化率经过12.5h可达到50%,更有利于可能的工业化连续生产。研究了整细胞催化合成D-D4FC反应中,pH值、缓冲液类型、底物浓度、加菌量、反应时间等条件的影响并进行了优化,探讨了反应中乳酸杆菌整细胞催化的可能机理。     

一种多肽固相合成方法与纯化策略研究

目的：多肽与小分子化学药物相比,具有生物活性高、特异性强、不容易产生耐药性等特点,是目前新型药物研发的重点领域。多肽的合成直接影响到多肽药物的作用机制以及药物效果,因此需要建立一种更加便捷、高效的多肽合成方法。方法：采用Fmoc固相合成法合成多肽HF01,通过比较氨基酸连接的反应体系以及氨基酸脱保护的反应体系,从中确定最优体系。利用乙酰化基团进行肽链末端保护,经肽链剪切制备干燥的粗肽,最后采用高效液相色谱仪与高分辨质谱仪联用对粗肽进行纯化。结果：确定多肽合成的连接和脱保护反应体系,并获得纯度高达98.3%的线性多肽。结论：建立了一种高效、便捷的多肽合成及纯化方法,提高了实验室合成多肽的效率,为多肽类药物的研发提供技术支撑。     

多肽融合标签的移除策略

多肽融合标签能够赋予目标蛋白新的特性,便于目标蛋白的定位、追踪、纯化以及结构和相互作用研究．但在很多情况下,尤其是研究蛋白质结构或分离纯化药用蛋白时,需要将多肽融合标签从融合蛋白上切除,以降低和消除多肽融合标签对目标蛋白结构和功能的影响．可用来切除多肽融合标签的方法主要有4种,即化学法、内切蛋白酶法、外切蛋白酶法以及自我剪切法．介绍和比较了每种方法的基本原理、应用以及研究进展．     

Structural Basis of Potent and Broad HIV-1 Fusion Inhibitor CP32M

CP32M is a newly designed peptide fusion inhibitor possessing potent anti-HIV activity, especially against T20-resistant HIV-1 strains. In this study, we show that CP32M can efficiently inhibit a large panel of diverse HIV-1 variants, including subtype B', CRF07_BC, and CRF01_AE recombinants and naturally occurring or induced T20-resistant viruses. To elucidate its mechanism of action, we determined the crystal structure of CP32M complexed with its target sequence. Differing from its parental peptide, CP621-652, the (621)VEWNEMT(627) motif of CP32M folds into two α-helix turns at the N terminus of the pocket-binding domain, forming a novel layer in the six-helix bundle structure. Prominently, the residue Asn-624 of the (621)VEWNEMT(627) motif is engaged in the polar interaction with a hydrophilic ridge that borders the hydrophobic pocket on the N-terminal coiled coil. The original inhibitor design of CP32M provides several intra- and salt bridge/hydrogen bond interactions favoring the stability of the helical conformation of CP32M and its interactions with N-terminal heptad repeat (NHR) targets. We identified a novel salt bridge between Arg-557 on the NHR and Glu-648 of CP32M that is critical for the binding of CP32M and resistance against the inhibitor. Therefore, our data present important information for developing novel HIV-1 fusion inhibitors for clinical use.     

血纤蛋白粘附肽与低分子量单链尿激酶融合产物活性分析

人工合成了血纤蛋白粘附肽基因,构建了粘附肽与低分子量单链尿激酶ｃＤＮＡ的融合基因,在大肠杆菌中表达了融合基因。融合基因表达产物的抗原性和天然尿激酶相同,并具有尿激酶的溶纤活性和粘附肽的抗纤维蛋白单体聚合的功能。     

血纤蛋白粘附肽与低分子量单链尿激酶融合基因在大肠杆菌中的表达

人工合成了血纤蛋白粘附肽基因,构建了粘附肽与低分子量单链尿激酶cDNA的融合基因,在大肠杆菌中表达了融合基因。融合基因表达产物的抗原性和天然尿激酶相同,并具有尿激酶的溶纤活性和粘附肽的抗纤维蛋白单体聚合的功能。     

纤维蛋白肽与低分子量尿激酶原融合蛋白的构建及性质

将人工合成的寡核苷酸片段进行定向连接后, 得到编码纤维蛋白β链N端(β 15～42)多肽的基因片段及连接区片段(linker), 再与低分子量尿激酶原(scuPA-32k) cDNA分子进一步连接后, 得到了Fβ(15～42)/scuPA-32k的融合基因.在大肠杆菌中经过IPTG诱导表达, 经过变性及复性, Zn²⁺螯合层析及Sephacryl S200凝胶层析后, 目的蛋白被纯化.SDS-聚丙烯酰胺凝胶电泳(PAGE)显示为一条蛋白质纯化条带, 分子质量为35 ku. 经纤维蛋白平板法测定比活为87 000 U/mg.经纤溶酶活化后的融合蛋白与低分子量尿激酶相比,对显色底物S2444酶促动力学性质相似.同时Fβ(15～42)/scuPA-32k具有较高的纤维蛋白的亲和性并能抑制纤维蛋白凝块的形成.     

抗菌肽CP10A在大肠杆菌中的融合表达

CP10A是一种由抗菌肽Indolicine经过序列改造,且对多数革兰氏阳性病源细菌具有较强抗菌活性的多肽序列。本研究根据已报道的CP10A氨基酸序列,兼顾大肠杆菌密码子偏好性,设计CP10A的核苷酸序列,利用PCR技术合成相应的DNA序列,后克隆构建重组表达载体pET32a（+）-CP10A,转入大肠杆菌AD494菌株。经IPTG诱导表达和15% SDS-PAGE电泳检测后发现产物以包涵体形式存在,且融合表达量占总蛋白的50%。在变性条件下经Ni-NTA亲合柱层析及复性,最终获得了较高纯度的可溶性重组蛋白。本研究首次实现了CP10A抗菌肽在大肠杆菌中的融合表达,为进一步研究其生物学活性及应用奠定了一定的基础,同时也为研究抗菌肽表达提供了一种方法。     

HIV—1融膜肽的编码DNA序列比较

通过分析GenBank中的全部95个HIV－1完整基因组序列,设计融膜肽“探针序列”,对所获得的95段融膜肽的编码DNA序列进行了翻译、对准和分析。得到融膜肽及其编码序称的“优势序列”及突变分布。     

抗菌肽GK1在大肠杆菌中的融合表达

为高效表达抗菌肽GK1并避免GK1的高抗菌活性对大肠杆菌宿主菌的致命影响, 将经改造后的人胰岛素原(mhPI)与GK1的融合基因(mhPI-GK1)克隆到表达载体pET28a中, 构建出表达质粒pET28a-mhPI-GK1, 转化至大肠杆菌BL21(DE3)中进行表达。融合蛋白在大肠杆菌中以包涵体形式表达, 表达量占菌体总蛋白的20%。经CNBr裂解、阳离子交换层析和RP-HPLC纯化后, 每升发酵液可获得5.7 mg纯度大于97%的重组GK1。质谱检测显示重组GK1的分子量为2794.0 D, 抑菌活性实验表明纯化后的重组GK1和化学合成GK1具有相同的抗菌活性。为利用基因工程方法大规模生产GK1奠定了基础。     

The Synthesis of Phosphopeptides Using Microwave-assisted Solid Phase Peptide Synthesis

A series of phosphorylated peptides were synthesised using microwave mediated solid phase peptide synthesis. Acidic cleavage of peptides from the solid support using microwave irradiation often resulted in reattachment of the phosphate benzyl protecting group to the peptide chain. However for most phosphopeptide sequences performing the cleavage reaction at room temperature in order to minimize this undesired alkylation was successful. Notably for phosphopeptides containing a methionine residue flanking the phosphorylated residue (for serine and threonine) the trifluoroacetic acid mediated cleavage afforded the benzylated side product as a major component. This detrimental process was not observed for a corresponding tyrosine containing sequence.     

Interaction of Influenza Virus Fusion Peptide with Lipid Membranes: Effect of Lysolipid

The effect of lysophosphatidylcholine (LPC) on lipid vesicle fusion and leakage induced by influenza virus fusion peptides and the peptide interaction with lipid membranes were studied by using fluorescence spectroscopy and monolayer surface tension measurements. It was confirmed that the wild-type fusion peptide-induced vesicle fusion rate increased several-fold between pH 7 and 5, unlike a mutated peptide, in which valine residues were substituted for glutamic acid residues at positions 11 and 15. This mutated peptide exhibited a much greater ability to induce lipid vesicle fusion and leakage but in a less pH-dependent manner compared to the wild-type fusion peptide. The peptide-induced vesicle fusion and leakage were well correlated with the degree of interaction of these peptides with lipid membranes, as deduced from the rotational correlation time obtained for the peptide tryptophan fluorescence. Both vesicle fusion and leakage induced by the peptides were suppressed by LPC incorporated into lipid vesicle membranes in a concentration-dependent manner. The rotational correlation time associated with the peptide’s tryptophan residue, which interacts with lipid membranes containing up to 25 mole % LPC, was virtually the same compared to lipid membranes without LPC, indicating that LPC-incorporated membrane did not affect the peptide interaction with the membrane. The adsorption of peptide onto a lipid monolayer also showed that the presence of LPC did not affect peptide adsorption.     

Synthesis and Immunological Evaluation of M Protein Targeted Tetra-Valent and Tri-Valent Group A Streptococcal Vaccine Candidates Based on the Lipid-Core Peptide System

Group A streptococcus (GAS) is responsible for causing many clinical complications including the relatively benign streptococcal pharyngitis and impetigo. However, if left untreated, these conditions may lead to more severe diseases such as rheumatic fever (RF) and rheumatic heart disease (RHD). These diseases exhibit high morbidity and mortality, particularly in developing countries and in indigenous populations of affluent countries. As RF and RHD only ever occur following GAS infection, a vaccine offers promise for their prevention. As such, we have investigated the use of the lipid-core peptide (LCP) system for the development of multi-valent prophylactic GAS vaccines. The current study has investigated the capacity of this system to adjuvant up to four different GAS peptide epitopes. Presented are the synthesis and immunological assessment of tetra-valent and tri-valent GAS LCP systems. We demonstrated their capacity to elicit systemic IgG antibody responses in B10.BR mice to all GAS peptide epitopes. The data also showed that the LCP systems were self-adjuvanting. These findings are particularly encouraging for the development of multi-valent LCP-based GAS vaccines.